Tapia Milagritos D, Findlow Helen, Idoko Olubukola T, Preziosi Marie-Pierre, Kulkarni Prasad S, Enwere Godwin C, Elie Cheryl, Parulekar Varsha, Sow Samba O, Haidara Fadima Cheick, Diallo Fatoumata, Doumbia Moussa, Akinsola Adebayo K, Adegbola Richard A, Kampmann Beate, Chaumont Julie, Martellet Lionel, Marchetti Elisa, Viviani Simonetta, Tang Yuxiao, Plikaytis Brian D, LaForce F Marc, Carlone George, Borrow Ray
Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore.
Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, United Kingdom.
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S514-20. doi: 10.1093/cid/civ672.
Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated.
African children vaccinated at 12-23 months of age with PsA-TT were followed for evaluation of antibody persistence up to 5 years after primary vaccination. Antibody persistence was evaluated by measuring group A serum bactericidal antibody (SBA) with rabbit complement and by a group A-specific IgG enzyme-linked immunosorbent assay (ELISA).
Group A antibodies measured by SBA and ELISA were shown to decline in the year following vaccination and plateaued at levels significantly above baseline for up to 5 years following primary vaccination.
A single dose of PsA-TT induces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccination.
ISRTCN78147026.
在非洲脑膜炎带开展A群脑膜炎球菌结合疫苗MenAfriVac（PsA-TT）大规模疫苗接种运动后，A群脑膜炎球菌引起的疾病几乎消失。对健康非洲幼儿的抗体持久性进行了调查。
对12至23个月龄接种PsA-TT的非洲儿童进行随访，以评估初次接种疫苗后长达5年的抗体持久性。通过用兔补体测量A群血清杀菌抗体（SBA）和采用A群特异性IgG酶联免疫吸附测定（ELISA）来评估抗体持久性。
通过SBA和ELISA测量的A群抗体在接种疫苗后的一年内下降，并在初次接种疫苗后的长达5年内稳定在显著高于基线的水平。
单剂量PsA-TT在接种疫苗后长达5年可诱导A群脑膜炎球菌抗体的长期持续水平。
ISRTCN78147026。
Zotero 插件